缺氧誘導因子穩定劑（Hypoxia-Inducible Factor Stabilizer, HIF Stabilizer）於透析病人之應用

Hypoxia-Inducible Factor Stabilizer Application in Maintenance Dialysis Patient

呂承翰(Cheng-Han Lu) ； 劉崇德(Chung-Te Liu)

《腎臟與透析》 35卷1期 (2023/03) Pp. 37-40

https://doi.org/10.6340/KD.202303_35(1).0006

摘要

透析病人貧血的主要臨床治療為給予紅血球生成素。然而，由於慢性發炎以及鐵質缺乏等因素，紅血球生成素治療常有阻抗性。缺氧誘導因子穩定劑為新型口服藥物，可增強紅血球生成素的產生，鐵質的吸收與利用率，且不受到慢性發炎反應的影響。目前，多篇臨床試驗中發現缺氧誘導因子穩定劑能夠改善透析病人的血色素，與紅血球生成素療效幾無差異。另一方面，上述臨床試驗顯示缺氧誘導因子穩定劑也未造成嚴重不良反應。然而，長期使用的副作用仍有待未來大規模臨床試驗來釐清。

關鍵字

缺氧誘導因子穩定劑 ； 貧血 ； 透析

並列摘要

Currently, the clinical treatment for anemia of dialysis patient is mainly erythropoietin (EPO). However, the efficacy of EPO is limited due to chronic inflammation and iron deficiency in dialysis patients, which cause EPO resistance in dialysis patients. Hypoxia-inducible factor stabilizer is a novel class of oral medication that increases the production of EPO, enhances the absorption and utilization of iron, and overcomes chronic inflammatory status. Recently, several clinical trials had shown that hypoxia-inducible factor stabilizer effectively improves anemia in dialysis patients to a similar extent compared with EPO. On the other hand, these trials showed that hypoxia-inducible factor stabilizers did not cause severe adverse effects. However, whether long-term use of hypoxia-inducible factor stabilizers causes adverse effect needs to be clarified in large clinical trials in the future.

並列關鍵字

hypoxia-inducible factor stabilizer ； anemia ； dialysis